



ASX ANNOUNCEMENT

29 November 2022

Renounceable Rights Offer – Extension of Closing Date & Updated Timetable

Transformative, concussion management technology company, **HITIQ Limited** (ASX: **HIQ**) (**HITIQ** or the **Company**) refers to its Renounceable Rights Offer (“Rights Issue Offer”) as announced to the ASX on 1 November 2022 and advises that the Closing Date of the Rights Issue Offer has been extended to Friday 9 December 2022.

As announced, the Company is undertaking the Rights Issue Offer to eligible shareholders to subscribe for eight (8) New Shares for every five (5) Shares held at an offer price of \$0.03 (3 cents) per share plus one (1) free attaching Option for every one (1) New Share subscribed under the Offer to raise up to \$6.35 million before costs.

The Rights Issue Offer timetable has been revised as follows:

Last date to extend Closing Date The Company may extend the Closing Date by giving at least 3 business days' notice to ASX prior to the Closing Date. Accordingly, the date the shares are expected to commence trading on ASX may vary.	Tuesday, 6 December 2022
Closing Date for acceptances under the Offer	5.00pm (Melbourne time) Friday 9 December 2022
Announcement of results of the issue	Wednesday, 14 December 2022
Last day for entity to issue the securities taken up in the pro rata issue Appendix 2A (applying for quotation of New Shares) to be lodged with ASX. Appendix 3G with respect to any unquoted securities.	Before 12.00pm (Sydney time) Friday 16 December 2022
Issue of holding statements Trading of New Shares expected to commence (T+2)	Tuesday, 20 December 2022

- ENDS -

HITIQ Limited
ACN 609 543 213
ASX: HIQ

[HITIQ.COM](https://www.hitiq.com)

Corporate Office
Level 2, 9-17 Raglan Street
South Melbourne VIC 3205

E: investors@hitiq.com

Directors

Otto Buttula
Michael Vegar
Phillip Carulli
Glenn Smith
Aidan Clarke

Non-Executive Chair
Managing Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

Authorised for release by the Board of HITIQ Limited.

For more information, contact:

Mike Vegar
CEO & MD
HITIQ Limited
investors@hitiq.com

Elvis Jurcevic
Investor Relations
+61 408 268 271
ej@hitiq.com

About HITIQ

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company's products support the identification, monitoring and management of sport related brain injury. HITIQ's product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company's first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.